(Q37998570)

26 August 2017

title

Molecular neurosurgery: vectors and vector delivery strategies (English)

1 reference

26 August 2017

0 references

Edward White

1

1 reference

26 August 2017

publication date

30 March 2012

1 reference

British Journal of Neurosurgery

26 August 2017

published in

1 reference

26 August 2017

volume

26

1 reference

26 August 2017

issue

6

1 reference

26 August 2017

page(s)

798-808

1 reference

Cellular and molecular neurosurgery: pathways from concept to reality--part II: vector systems and delivery methodologies for gene therapy of the central nervous system

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Cellular and molecular neurosurgery: pathways from concept to reality--part I: target disorders and concept approaches to gene therapy of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Blood-brain barrier transport of non-viral gene and RNAi therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

In vivo and ex vivo MRI detection of localized and disseminated neural stem cell grafts in the mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Adenovirus-mediated gene transfer to the brain: methodological assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Convection-enhanced delivery of macromolecules in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Adeno-associated virus vector-mediated transduction in the cat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Parkinson disease, brain volumes, and subthalamic nucleus stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

An evaluation of the relationships between catheter design and tissue mechanics in achieving high-flow convection-enhanced delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

The development of an implantable catheter system for chronic or intermittent convection-enhanced delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Effect of ependymal and pial surfaces on convection-enhanced delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Evaluation and Optimization of the Administration of Recombinant Adeno-Associated Viral Vectors (Serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by Convection-Enhanced Delivery to the Striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

What is immune privilege (not)?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Real-time imaging and quantification of brain delivery of liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Suppression of human glioma growth by adenovirus-mediated Rb gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Lentiviral-mediated delivery of Bcl-2 or GDNF protects against excitotoxicity in the rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Effective gene therapy with nonintegrating lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Nonviral approaches for neuronal delivery of nucleic acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Antitumor effect of an adeno-associated virus vector containing the human interferon-beta gene on experimental intracranial human glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

The subthalamic nucleus in the context of movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Imaging‐guided convection‐enhanced delivery and gene therapy of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Immune responses to AAV in a phase I study for Canavan disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02688697.2012.671972

10.3109/02688697.2012.671972

21 January 2018

Identifiers

DOI

1 reference

release_jvkd5uhowvgwpgr6tpypa2kvyq

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jvkd5uhowvgwpgr6tpypa2kvyq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference